Refractory Anemia With Excess Blasts in Transformation
Also known as: Refractory anemia with excess blasts in transformation / Acute myeloblastic leukemia, minimal differentiation / Refractory anaemia with excess blasts in transformation / Myelodysplastic syndrome transformation
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB00928 | Azacitidine | A pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent. [PubChem] |
| DB01262 | Decitabine | Decitabine is indicated for treatment of patients with myelodysplastic syndrome (MDS). It is a chemical analogue of cytidine, a nucleoside present in DNA and RNA. Cells in the presence of Decitabine incorporate it into DNA during replication and RNA during transcription. The incorporation of Decitabine into DNA or RNA inhibits methyltransferase thereby causing demethylation in that sequence. This adversely affects the way that cell regulatory proteins are able to bind to the DNA/RNA substrate. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB00928 | Azacitidine | DNA (cytosine-5)-methyltransferase 1 | target |
| DB00928 | Azacitidine | Cytidine deaminase | enzyme |
| DB00928 | Azacitidine | DNA | target |
| DB00928 | Azacitidine | RNA | target |
| DB01262 | Decitabine | DNA | target |
| DB01262 | Decitabine | DNA (cytosine-5)-methyltransferase 1 | target |
| DB01262 | Decitabine | Deoxycytidine kinase | enzyme |